معرفی
Didier Guillemot is a Professor and Head of the Epidemiology and Modelling of Antibacterial Evasion (EMAE) research unit within the Global Health Department at the Institut Pasteur in Paris, France. He leads multiple research projects focused on antimicrobial resistance, epidemiology, and public health, including i-Share, Primavera, and I-BIRD. His work bridges mathematical modeling, biostatistics, and clinical epidemiology to understand and combat the spread of antibiotic-resistant bacteria in both high- and low-income countries.
His primary research interests include:
- Antibiotic resistance and its dissemination
- Mathematical and computational modeling of infectious diseases
- Pharmacoepidemiology and public health
- Microbiome and horizontal gene transfer
- Healthcare-associated infections and sepsis outcomes
- Global health with a focus on low-resource settings
His recent publications demonstrate a strong trend toward using large-scale data (medico-administrative databases, cohort studies) and dynamic modeling to assess the burden of antimicrobial resistance, evaluate interventions, and understand transmission dynamics in both community and hospital environments. His work frequently involves international collaborations and addresses pressing public health challenges such as the impact of the COVID-19 pandemic on antibiotic resistance and sepsis care pathways.
Scientific awards:
- No specific awards mentioned in the provided text.
Didier Guillemot actively supervises research through his role as Principal Investigator on multiple projects, mentoring PhD students and post-doctoral researchers within his unit. He has received funding for various research initiatives, including those focused on antibiotic resistance in Africa (SARA project) and student health (i-Share). His work is supported by national and international grants, often in collaboration with institutions like Cnam and Sorbonne University.
He leads the EMAE research unit, which conducts interdisciplinary research involving epidemiological follow-up, database analysis, and dynamic modeling to evaluate the clinical and economic benefits of antibacterial innovations and control strategies.
